SYNEOS HEALTH, INC.

(SYNH)
  Report
Delayed Nasdaq  -  05/27 04:00:01 pm EDT
75.18 USD   +4.53%
05/25Cabral Gold to Raise up to $5 Million in Public Offering of Units
MT
05/24Syneos Health to Present at Upcoming Investor Conferences
AQ
05/24Guggenheim Starts Syneos Health at Buy With $81 Price Target
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Syneos Health Announces Directors Appointments

01/18/2022 | 06:16am EDT

Syneos Health announced it has appointed two new independent directors, Barbara W. Bodem and Alfonso G. Zulueta, to its Board of Directors. Following the appointment of Ms. Bodem and Mr. Zulueta, the Syneos Health Board is comprised of 11 directors, 10 of whom are independent. Ms. Bodem will serve as a Class I director and will serve on the Company’s Audit Committee and Mr. Zulueta will serve as a Class III director. Ms. Bodem currently serves on the board of directors of Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a clinical-stage precision oncology company, where she serves as Chair of the Audit Committee and as a member of the Compensation Committee. Mr. Zulueta currently serves on the board of directors of CTS Corporation (NYSE: CTS), a global manufacturer of sensors, connectivity components, and actuators, where he serves on the Audit Committee; Compensation Committee; and Nominating, Governance, and Sustainability Committee.


© S&P Capital IQ 2022
All news about SYNEOS HEALTH, INC.
05/25Cabral Gold to Raise up to $5 Million in Public Offering of Units
MT
05/24Syneos Health to Present at Upcoming Investor Conferences
AQ
05/24Guggenheim Starts Syneos Health at Buy With $81 Price Target
MT
05/10Syneos Health Leaders Recognized by HBA
AQ
05/02Syneos Health Names Michelle Keefe as Next Chief Executive Officer
AQ
05/02Syneos Health Reports First Quarter 2022 Results
AQ
04/29SYNEOS HEALTH, INC. : Change in Directors or Principal Officers, Financial Statements and ..
AQ
04/29SYNEOS HEALTH : Q1 2022 Financial Results Presentation
PU
04/29Syneos Health Promotes Michelle Keefe to CEO, Michael Brooks to COO
MT
04/29Syneos Health's Q1 Adjusted Earnings, Revenue Increase; Boosts FY22 EPS Guidance
MT
More news
Analyst Recommendations on SYNEOS HEALTH, INC.
More recommendations
Financials (USD)
Sales 2022 5 669 M - -
Net income 2022 297 M - -
Net Debt 2022 2 684 M - -
P/E ratio 2022 26,3x
Yield 2022 -
Capitalization 7 712 M 7 712 M -
EV / Sales 2022 1,83x
EV / Sales 2023 1,63x
Nbr of Employees 26 751
Free-Float 59,7%
Chart SYNEOS HEALTH, INC.
Duration : Period :
Syneos Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNEOS HEALTH, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 75,18 $
Average target price 91,55 $
Spread / Average Target 21,8%
EPS Revisions
Managers and Directors
Michelle Keefe Chief Executive Officer & Director
Jason Michael Meggs Chief Financial Officer
John M. Dineen Chairman
Larry A Pickett Chief Information & Digital Officer
Baba Shetty President-Technology & Data Solutions
Sector and Competitors
1st jan.Capi. (M$)
SYNEOS HEALTH, INC.-26.78%7 712
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478